Clinical trials: Type of Delivery
Diphtheria, Hepatitis B
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
The purpose of the study is to demonstrate consistent results in 3 production lots of Hib-MenAC vaccine when extemporaneously mixed with Tritanrix™-HepB and administered as a single injection, with respect to immunogenicity…
- Conditions
- Diphtheria, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis
- Trial name
- NCT00317161
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine.
- Trial name
- ORA2 (NCT00990444)
- Testing
- Insulin in Dextran Matrix
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Bows Pharmaceuticals AG
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03743285
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Hepatocellular
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00034333
- Testing
- MTC-DOX for Injection
- Where
- 29 sites in United States, Austria and 6 more
- Volunteers
- 240 people
- Sponsor
- FeRx
Innate Immunity
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate the immunity of infant born from caesarian section and fed with formula milk…
- Trial name
- NCT04256356
- Testing
- Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder, Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder, Feeding infants with standard formula milk
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Heinz Italia SpA
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Limb-Girdle Muscular Dystrophy, Type 2E
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
The proposed clinical trial is the first-in-human, single-center, open-label, gene delivery study of SRP-9003 (bidridistrogene xeboparvovec) in participants with LGMD2E.
- Trial name
- NCT03652259
- Testing
- SRP-9003
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sarepta Therapeutics, Inc.
Pompe Disease, Pompe Disease (Late-onset)
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzyme replacement therapy (ERT).
- Conditions
- Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
- Trial name
- NCT04093349
- Testing
- SPK-3006
- Where
- 29 sites in United States, Canada and 6 more
- Volunteers
- 4 people
- Sponsor
- Spark Therapeutics, Inc.
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
PBGM01 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the brain and peripheral tissues.
- Conditions
- GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
- Trial name
- Imagine-1 (NCT04713475)
- Testing
- PBGM01
- Where
- 7 sites in United States, Brazil and 2 more
- Volunteers
- 26 people
- Sponsor
- Gemma Biotherapeutics
Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.
- Trial name
- NCT00104091
- Testing
- TP-38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrent High Grade Gliomas, Glioblastoma (GBM)
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
ALERT-1 is a Phase 1/2 study evaluating the safety and preliminary anti-tumor activity of SRN-101, an investigational gene therapy, in adults with recurrent high-grade glioma. High-grade glioma is a type of brain cancer.
- Conditions
- Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- ALERT-1 (NCT07902037)
- Testing
- SRN-101
- Volunteers
- 40 people
- Sponsor
- Siren Biotechnology
Dravet Syndrome
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
WAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to <84 months. The study follows an open-label, dose-escalation design.
- Trial name
- NCT06112275
- Testing
- ETX101
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Encoded Therapeutics
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00569998
- Testing
- NovoPen™ 4, NovoPen® 3
- Where
- 23 sites in Austria, Germany and 3 more
- Volunteers
- 208 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03848767
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
An Audit of the Impact of Tailored Information Delivered Via a Digital Learning Platform
The study intends to audit the impact of optimal insulin injection technique on clinical parameters and self-care behaviour of insulin treated diabetes patients in a prospective manner with a follow-up of 6 months.
- Trial name
- NCT04007003
- Testing
- training in optimal insulin injection technique
- Where
- 9 sites in Belgium
- Volunteers
- 170 people
- Sponsor
- Becton, Dickinson and Company
Limb Girdle Muscular Dystrophy
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4).
- Trial name
- NCT05876780
- Testing
- SRP-9003
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sarepta Therapeutics, Inc.
Liver Cancer
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
Brachytherapy is a recent technique used in the treatment of tumours and involves the use of radioactive sources brought into close contact with the target tissues.
- Trial name
- NCT00247260
- Testing
- 32P BioSilicon
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- pSiVida Limited
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 1 Diabetes
Omnipod 5 System Compared to Pump Therapy
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or…
- Trial name
- NCT05409131
- Testing
- Omnipod 5 System
- Where
- 14 sites in United States, France
- Volunteers
- 196 people
- Sponsor
- Insulet Corporation
Advanced Solid Tumor
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with…
- Trial name
- ASCENT-1 (NCT07751042)
- Testing
- STX-003, KEYTRUDA®
- Where
- 4 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Strand Therapeutics Inc.